Keros Therapeutics, Inc. (KROS) Profit Margins
Over the twelve months to 2026-06-30, Keros Therapeutics, Inc. (KROS) had operating margin -675.8%, net margin -553.9%, free cash flow margin -322.9%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KROSKeros Therapeutics, Inc.Follow KROS — free
—
Price chart with a free account
- Market cap
- 223.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating margin | -280.5% | -112543.7% | -5939.0% | 27.7% | -675.8% | |
| Net margin | -292.3% | -101319.2% | -5277.5% | 35.7% | -553.9% | |
| FCF margin | -314.3% | -84087.4% | -4585.9% | 43.4% | -322.9% |
USD millions · SEC XBRL
Keros Therapeutics, Inc. — questions
- What is Keros Therapeutics, Inc.'s operating margin?
- -675.8% over the twelve months to 2026-06-30.
- What is Keros Therapeutics, Inc.'s net profit margin?
- -553.9% over the twelve months to 2026-06-30.
Every figure on this page comes from Keros Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.